Tan Tock Seng Hospital | Clinical Research and Innovation Office
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exclusion Criteria for Participants Receiving Pembrolizumab:
Primary purpose
Allocation
Interventional model
Masking
261 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal